No Data
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Intellia Therapeutics Is Maintained at Neutral by Citigroup
Intellia Therapeutics Is Maintained at Neutral by Citigroup
Citi: Maintains Intellia Therapeutics (NTLA.US) rating, adjusted from neutral to neutral, and adjusted the target price from $31.00 to $29.00.
Citi: Maintains Intellia Therapeutics (NTLA.US) rating, adjusted from neutral to neutral, and adjusted the target price from $31.00 to $29.00.
Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $29
Citigroup analyst David Lebowitz maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target from $31 to $29.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript